COVID-19 Vaccines
Conditions
Keywords
COVID-19, SARS-CoV-2, peptide, vaccine, subunit, protein
Brief summary
This is a multicenter, international, randomized, active-controlled platform study with each sub-study designed to randomize subjects to receive a single injection with UB-612 or a comparator COVID-19 vaccine in 1:1 ratio.
Detailed description
The current platform protocol is designed to determine the safety and immunizing activity of a booster dose of 100 μg UB-612 in patients who have received a different vaccine 3 months or more before the study start (i.e., Day 1). The randomized, active-controlled multicenter study sponsored by Vaxxinity will be conducted in several countries under a master platform protocol outlining common objectives, endpoints, population, study design, and data analysis. The platform protocol is designed for multiple sub-studies to be implemented at any time, each independently addressing the same set of scientific questions aimed to evaluate the immune responses after a booster injection with UB-612 vaccine candidate and a particular comparator COVID-19 vaccine product.
Interventions
BIOLOGICALUB-612
UB-612 (100µg), 0.5mL suspension, intramuscular injection
BIOLOGICALBNT162b2 vaccine
BNT162b2 vaccine (30µg), 0.3mL suspension, intramuscular injection
BIOLOGICALChAdOx1-S vaccine
ChAdOx1-S vaccine, 0.5 mL suspension with approximately 5.0 × 10˄10 viral particles, intramuscular injection
BIOLOGICALSinopharm BIBP
Sinopharm BIBP COVID-19 vaccine, 0.5mL (4µg) suspension, intramuscular injection
Sponsors
Syneos Health
Coalition for Epidemic Preparedness Innovations
Vaxxinity, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Intervention model description
Platform trial with multiple sub-studies. Each sub-study has two treatment arms: active comparator and IMP.
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Signed and dated informed consent/assent after reading the consent/assent form and having adequate opportunity to discuss the study with an investigator or designee. 2. Documented fully vaccinated with primary series of a comparator vaccine. Primary immunization is defined as 2 doses spaced approximately 3-16 weeks apart. The last dose of the previous vaccine must have been administered at least three (3) months (Pfizer at least (5) months) prior to Day 1, taking into consideration the current local and national regulations, and according to details related to individual comparators provided in relevant sub-studies. Documentation, such as the National Health Service (NHS) COVID Pass, United States Centers for Disease Control vaccine card, or equivalent documentation (e.g., medical records, vaccine passport; in accordance with local approved vaccination record documentation) will be required for proof of vaccination, vaccine manufacturer and vaccination dates. 3. No clinically significant health problems that could affect the safety of the subject, as determined by the investigator by medical history, laboratory tests and physical examination. May have a stable pre-existing medical condition that did not require significant change in medication or hospitalization in 3 months before screening or which, in the judgement of the investigator is unlikely to require a significant change in therapy or hospitalization for worsening disease in the 3 months after Day 1. 4. Negative SARS-CoV-2 reverse transcriptase-polymerase chain reaction (RT-PCR) or antigen test within 24-48 hours prior to receipt of injections on Day 1. 5. Female subjects of non-childbearing potential may be enrolled. 6. Males and WOCBP, 16 years or older, may be enrolled in the study if they are willing to practice abstinence from sexual intercourse or are willing to use acceptable methods of contraception as described below, from the time of signing the informed consent/assent during the screening period through study product injection on Day 1 and until completion of Day 29. Acceptable methods of contraception should be consistent with local availability/regulations regarding the use of contraceptive methods for those participating in clinical trials. 7. For WOCBP, a serum or urine pregnancy test must be negative at Screening and on the day of study product injection. 8. Must be able to read, understand, and complete questionnaires and diary entries. 9. Plans to reside within study area for the duration of the study. 10. Able to comply with study procedures for the full duration of the study, in the opinion of the investigator.
Exclusion criteria
1. Known history of COVID-19 or SARS-CoV-2 infection within six (6) months prior to vaccination (Day 1). 2. Receipt of a booster COVID-19 vaccination in addition to the primary vaccine series. 3. Presence of fever \>100.4°F/38°C or other signs or symptoms of COVID-19 (e.g., chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, or diarrhea) within 1 week prior to Day 1 study product injection. Screening and/or study product injection may be rescheduled at the discretion of the investigator. 4. Clinical manifestations of systemic diseases considered by the investigator to impact safety or immunogenicity. 5. Prior history of pericarditis or myocarditis of any etiology. 6. Prior history of thrombosis of major vessels, including cerebrovascular or splanchnic thrombosis or of thrombosis with thrombocytopenia syndrome 7. History of anaphylaxis (vaccine related or not). 8. Chronic kidney disease with dialysis. 9. Receipt of systemic corticosteroids (≥0.5 mg/kg per day of prednisone or equivalent)for ≥7 days is prohibited from 28 days before enrollment through conclusion of the study. Topical, inhaled, intra-nasal, intra-articular or intra-bursal administration of corticosteroids is permitted. 10. Receipt of any cytotoxic or immunosuppressive drug or biologics six (6) months prior to Day 1 visit. 11. Receipt of any investigational drug within six (6) months prior to Day 1 visit. 12. Subject received or plans to receive a live attenuated vaccine or licensed adjuvanted(non-aluminum compound) vaccination within 28 days before or after planned administration of study vaccine (Day 1) or another type of vaccine (including influenza vaccine) within 14 days prior to or after planned administration of study vaccine on Day1 visit. 13. Human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg) positive; hepatitis C virus (HCV) antibody positive subjects may be tested for RNA and if negative may be enrolled. 14. Any Grade 2 or greater clinical or laboratory abnormalities at screening results. Grade 1 abnormal clinical or laboratory adverse event screening test results which, according to the investigator, are non-clinically significant would not disqualify a potential subject. Clinical or laboratory screening tests may be repeated once to exclude transient abnormalities. 15. Immunocompromised state (weakened immune system) from solid organ transplant, immunosuppressive or immunodeficient state, autoimmune diseases, asplenia and, recurrent severe infections. 16. Have an active malignancy or history of metastatic or hematologic malignancy except non-melanoma skin cancers. 17. Pregnant or breastfeeding female, or female who intends to become pregnant during the study period. 18. Administration of immunoglobulins and/or any blood products within the 120 days preceding Day 1 or planned administration during the study period. 19. Bleeding disorder considered a contraindication to intramuscular injection or phlebotomy. 20. Bilateral tattoos or scars at the deltoid sites of intramuscular (IM) injection that would obscure examination of injection site reactions. 21. Behavioral, cognitive, or psychiatric disease that, in the opinion of the Principal Investigator or his or her representative physician, affects the subject's ability to understand and cooperate with all study protocol requirements. 22. Any alcohol or drug abuse over the 12 months prior to enrollment in the study that has caused medical, professional, or family problems, indicated by clinical history. 23. Grade 2 or higher hypertension (systolic \>160 mm Hg and/or diastolic \>100 mm Hg). 24. Any other condition that, in the opinion of the Principal Investigator or his/her representative physician, could put the safety/rights of potential subjects at risk or prevent them from complying with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of serious adverse events | Day 387 after injection | SAE are reported through the study |
| Boost in neutralizing antibody titers against Wuhan strain at Day 29 | Day 29 after injection | Geometric Mean Titer Ratios of neutralizing antibodies at Day 29 determined using replicating or pseudotyped virus |
| Presence of adverse events of special interest | Day 387 after injection | AESI are reported throughout the study |
| Presence of medically attended adverse events | Day 387 after injection | AE that leads to an unscheduled visit |
| Presence of unsolicited local or systemic reactions | Day 29 after injection | Any AE reported by the subject that is not specified as a solicited |
| Presence of solicited local or systemic reactions | Day 8 after injection | Local: pain, tenderness, erythema, induration, pruritis. Systemic: Nausea, diarrhea, headache, fatigue, myalgia, chills, joint pain, rash |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Kinetics and duration of antibody response - GMFI via neutralizing antibodies | Day 1 to Day 15, Day 29, and Months 6 and 12 | Geometric Mean Fold Increase of neutralizing antibodies determined using replicating or pseudotyped virus |
| Kinetics and duration of antibody response - GMFI via binding to S1-RBD | Day 1 to Day 15, Day 29, and Months 6 and 12 | Geometric Mean Fold Increase of IgG antibodies titers measured by direct S1-RBD binding ELISA |
| Kinetics and duration of antibody response - AUC via binding to S1-RBD | Day 15 to Month 12 | Area under the curve (AUC) by treatment group and virus variants calculated from IgG antibody response measured by direct S1-RBD binding ELISA |
| Kinetics and duration of antibody response - GMT via neutralizing antibodies | Days 15, 29, and Months 6 and 12 | Geometric Mean Titers measured by neutralizing antibody response by treatment group and virus variants |
| Kinetics and duration of antibody response - GMT via binding to S1-RBD | Days 15, 29, and Months 6 and 12 | Geometric Mean Titers measured by IgG antibody response measured by direct S1-RBD binding ELISA |
| Kinetics and duration of antibody response - Reverse Cumulative Distribution Curve via neutralizing antibodies | Day 29 and Month 6 and 12 | Distribution of neutralizing antibody titers displayed as reverse cumulative distribution curves by treatment group and virus variants measured by neutralizing antibody response |
| Kinetics and duration of antibody response - Reverse Cumulative Distribution Curve via binding to S1-RBD | Day 29 and Month 6 and 12 | Distribution of IgG antibody titers displayed as reverse cumulative distribution curves by the treatment group and virus variant measured IgG antibody response measured by direct S1-RBD binding ELISA |
| Kinetics and duration of antibody response - AUC via neutralizing antibodies | Day 15 to Month 12 | Area under the curve (AUC) by treatment group and virus variants calculated from neutralizing antibody response determined using replicating or pseudotyped virus |
| Boost in neutralizing antibody titers against Omicron strain at Day 29 | Day 29 after injection | Geometric Mean Titer Ratios of neutralizing antibodies at Day 29 determined using replicating or pseudotyped virus |
| Responders determined on Day 29 (Wuhan) | Day 1 to 29 after injection | Proportion of subjects with ≥4-fold antibody titer rise from Day 1 to Day 29 |
| Responders determined on Day 29 (Omicron) | Day 1 to 29 after injection | Proportion of subjects with ≥4-fold antibody titer rise from Day 1 to Day 29 |
| Kinetics and duration of antibody response - Responders via neutralizing antibodies | Day 1 to Day 15, Day 29, and Months 6 and 12 | Proportion of subjects with ≥4-fold antibody titer rise over the life of trial measured by neutralizing antibodies determined using replicating or pseudotyped virus |
| Kinetics and duration of antibody response - Responders via binding to S1-RBD | Day 1 to Day 15, Day 29, and Months 6 and 12 | Proportion of subjects with ≥4-fold antibody titer rise over the life of trial measured by IgG antibodies titers measured by direct S1-RBD binding ELISA |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ability to boost cellular immunity | Days 1, 15 and 29, and Months 6 and 12 | Cytokine secreting spots per million cells and % cells staining for cytokines measured by ELISpot and ICS |
| Ability to boost humoral immunity (neutralizing) against additional variant - GMFI via neutralizing antibodies | Day 1 and Day 29 | Geometric Mean Fold Increase in neutralizing antibody titers measured additional variant replicating or pseudotyped viruses |
| Ability to boost humoral immunity (neutralizing) against additional variant - GMR via neutralizing antibodies | Day 1 and Day 29 | Geometric Mean Titer Ratios in neutralizing antibody titers measured using additional variant replicating or pseudotyped viruses |
| Ability to boost humoral immunity (neutralizing) against additional variant - GMT via neutralizing antibodies | Day 1 and Day 29 | Geometric Mean Titers in neutralizing antibody titers measured using additional variant replicating or pseudotyped viruses |
| Ability to boost humoral immunity (non-neutralizing) | Day 1 and Day 29 | Fc-mediated antibody ADCP (antibody dependent cell-mediated phagocytosis) responses |
Countries
Panama, Philippines, United States
Outcome results
None listed